Chapter 028. Sleep Disorders (Part 6) doc

Sleep Disorders Part 6 Evaluation of Insomnia Insomnia is the complaint of inadequate sleep; it can be classified according to the nature of sleep disruption and the duration of the com

Chapter 028 Sleep Disorders

(Part 6)

Evaluation of Insomnia

Insomnia is the complaint of inadequate sleep; it can be classified according to the nature of sleep disruption and the duration of the complaint

Insomnia is subdivided into difficulty falling asleep (sleep onset insomnia), frequent or sustained awakenings (sleep maintenance insomnia), early morning awakenings (sleep offset insomnia), or persistent sleepiness/fatigue despite sleep

of adequate duration (nonrestorative sleep) Similarly, the duration of the

symptom influences diagnostic and therapeutic considerations An insomnia complaint lasting one to several nights (within a single episode) is termed

transient insomnia and is typically the result of situational stress or a change in sleep schedule or environment (e.g., jet lag disorder) Short-term insomnia lasts

from a few days to 3 weeks Disruption of this duration is usually associated with

more protracted stress, such as recovery from surgery or short-term illness Long-term insomnia, or chronic insomnia, lasts for months or years and, in contrast with

short-term insomnia, requires a thorough evaluation of underlying causes (see below) Chronic insomnia is often a waxing and waning disorder, with spontaneous or stressor-induced exacerbations

An occasional night of poor sleep, typically in the setting of stress or excitement about external events, is both common and without lasting consequences However, persistent insomnia can lead to impaired daytime function, injury due to accidents, and the development of major depression In addition, there is emerging evidence that individuals with chronic insomnia have increased utilization of health care resources, even after controlling for co-morbid medical and psychiatric disorders

All insomnias can be exacerbated and perpetuated by behaviors that are not

conducive to initiating or maintaining sleep Inadequate sleep hygiene is

characterized by a behavior pattern prior to sleep or a bedroom environment that is not conducive to sleep Noise or light in the bedroom can interfere with sleep, as can a bed partner with periodic limb movements during sleep or one who snores loudly Clocks can heighten the anxiety about the time it has taken to fall asleep Drugs that act on the central nervous system, large meals, vigorous exercise, or hot showers just before sleep may all interfere with sleep onset Many individuals participate in stressful work-related activities in the evening, producing a state

incompatible with sleep onset In preference to hypnotic medications, patients should be counseled to avoid stressful activities before bed, develop a soporific bedtime ritual, and to prepare and reserve the bedroom environment for sleeping Consistent, regular rising times should be maintained daily, including weekends

Primary Insomnia

Many patients with chronic insomnia have no clear, single identifiable underlying cause for their difficulties with sleep Rather, such patients often have multiple etiologies for their insomnia, which may evolve over the years In addition, the chief sleep complaint may change over time, with initial insomnia predominating at one point, and multiple awakenings or nonrestorative sleep occurring at other times Subsyndromal psychiatric disorders (e.g., anxiety and mood complaints), negative conditioning to the sleep environment (psychophysiologic insomnia, see below), amplification of the time spent awake (paradoxical insomnia), physiologic hyperarousal, and poor sleep hygiene (see above) may all be present As these processes may be both causes and consequences of chronic insomnia, many individuals will have a progressive course to their symptoms in which the severity is proportional to the chronicity, and much of the complaint may persist even after effective treatment of the initial inciting etiology Treatment of insomnia is often directed to each of the putative contributing factors: behavior therapies for anxiety and negative conditioning (see

below), pharmacotherapy and/or psychotherapy for mood/anxiety disorders, and

an emphasis on maintenance of good sleep hygiene

If insomnia persists after treatment of these contributing factors, empirical pharmacotherapy is often used on a nightly or intermittent basis A variety of sedative compounds are used for this purpose Alcohol and antihistamines are the most commonly used nonprescription sleep aids The former may help with sleep onset but is associated with sleep disruption during the night and can escalate into abuse, dependence, and withdrawal in the predisposed individual Antihistamines may be of benefit when used intermittently but often produce rapid tolerance and may have multiple side effects (especially anticholinergic), which limit their use, particularly in the elderly Benzodiazepine-receptor agonists are the most effective and well-tolerated class of medications for insomnia The broad range of half-lives allows flexibility in the duration of sedative action The most commonly prescribed agents in this family are zaleplon (5–20 mg), with a half-life of 1–2 h; zolpidem (5–10 mg) and triazolam (0.125–0.25 mg), with half-lives of 2–3 h; eszopiclone (1–3 mg), with a half-life of 5.5–8 h; and temazepam (15–30 mg) and lorazepam (0.5–2 mg), with half-lives of 6–12 h Generally, side effects are minimal when the dose is kept low and the serum concentration is minimized during the waking hours (by using the shortest-acting, effective agent) Recent data suggest that at least one benzodiazepine receptor agonist (eszopiclone) continues to be effective for 6 months of nightly use However, longer durations of

use have not been evaluated, and it is unclear whether this is true of other agents in this class Moreover, with even brief continuous use of benzodiazepine-receptor agonists, rebound insomnia can occur upon discontinuation The likelihood of rebound insomnia and tolerance can be minimized by short durations of treatment, intermittent use, or gradual tapering of the dose For acute insomnia, nightly use of

a benzodiazepine receptor agonist for a maximum of 2–4 weeks is advisable For chronic insomnia, intermittent use is recommended, unless the consequences of untreated insomnia outweigh concerns regarding chronic use Benzodiazepine receptor agonists should be avoided, or used very judiciously, in patients with a history of substance or alcohol abuse The heterocyclic antidepressants (trazodone, amitriptyline, and doxepin) are the most commonly prescribed alternatives to benzodiazepine receptor agonists due to their lack of abuse potential and lower cost Trazodone (25–100 mg) is used more commonly than the tricyclic antidepressants as it has a much shorter half-life (5–9 h), has much less anticholinergic activity (sparing patients, particularly the elderly, constipation, urinary retention, and tachycardia), is associated with less weight gain, and is much safer in overdose The risk of priapism is small (~1 in 10,000)